Aktueller Stand der PSMA-PET-Diagnostik beim Prostatakarzinom

Fabian Spohn; Jan Philipp Radtke; Charlotte Düwel; Matthias Eiber; Stefan Körber; Claudia Gasch; Clemens Kratochwil; Uwe Haberkorn; Markus Hohenfellner; Jürgen Debus; Frederik L. Giesel

doi:10.1055/a-0621-3205

Der Nuklearmediziner, Table of Contents

Der Nuklearmediziner 2018; 41(03): 232-246
DOI: 10.1055/a-0621-3205

CME-Fortbildung

Aktueller Stand der PSMA-PET-Diagnostik beim Prostatakarzinom

Current status of PSMA-PET diagnostics in prostate cancer

Fabian Spohn

¹Abteilung für Nuklearmedizin, UK-HD, Heidelberg

,

Jan Philipp Radtke

²Abteilung für Urologie, UK-HD, Heidelberg

,

Charlotte Düwel

³Klinik für Urologie, Technische Universität München, München

,

Matthias Eiber

⁴Klinik und Poliklinik für Nuklearmedizin, Technische Universität München, München

,

Stefan Körber

⁵Abteilung für Radioonkologie, UK-HD, Heidelberg

,

Claudia Gasch

²Abteilung für Urologie, UK-HD, Heidelberg

,

Clemens Kratochwil

¹Abteilung für Nuklearmedizin, UK-HD, Heidelberg

,

Uwe Haberkorn

⁶KKE Nuklearmedizin, DKFZ, Heidelberg

,

Markus Hohenfellner

²Abteilung für Urologie, UK-HD, Heidelberg

,

Jürgen Debus

⁵Abteilung für Radioonkologie, UK-HD, Heidelberg

,

Frederik L. Giesel

¹Abteilung für Nuklearmedizin, UK-HD, Heidelberg

› Author Affiliations
Subject Editor: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. Frederik L. Giesel, Heidelberg.

Abstract

Dieser Artikel gibt ein Update zum aktuellen Stand der PSMA-PET-Diagnostik beim Prostatakarzinom. Dabei soll auf die Schwerpunkte des Primärstagings und der Diagnostik beim biochemischen Rezidiv eingegangen sowie Aspekte aus uroonkologischer und strahlentherapeutischer Sicht miteinbezogen werden.
Durch die andauernde Weiterentwicklung und Optimierung der PSMA-gerichteten Tracer bekommt die molekulare Bildgebung mittels PET/CT einen immer höheren Stellenwert in dem Patientenmanagement, was sich auch in der expliziten Erwähnung aktuellster nationaler sowie internationaler Leitlinien widerspiegelt.

Abstract

This article gives an update on the current status of PSMA-PET diagnostics in prostate cancer. For this purpose, we want to focus on primary staging and in patient with biochemical recurrence. Furthermore, also important clinical aspects from the uro- and radio-oncology are covered.

Due to advanced development and optimization of PSMA targeted tracers molecular imaging such as PET/CT will become an important asset in prostate cancer which also underlying the consideration in the recent national and international guidelines.

Schlüsselwörter

Prostatakarzinom - PSMA - PET - Staging - Rezidiv

Keywords

prostate cancer - PSMA - PET - staging - recurrence

Full Text

References

Literatur
1 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30
2 Schoder H. 2-[18F]Fluoro-2-Deoxyglucose positron emission tomography for the detection of disease in patients with prostatespecific antigen relapse after radical prostatectomy. Clin Cancer Res 2005; 11: 4761-4769
3 Evangelista L, Guttilla A, Zattoni F. et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013; 63: 1040-1048
4 Fanti S, Minozzi S, Castellucci P. et al. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. Eur J Nucl Med Mol Imaging 2016; 43: 55-69
5 Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung. Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Im Internet: http://www.awmf.org/uploads/tx_szleitlinien/043-022OLk_S3_Prostatakarzinom_2016-12.pdf
6 Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6 (Suppl. 10) S13-S18
7 Bostwick DG, Pacelli A, Blute M. et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases. Cancer 1998; 82: 2256-2261
8 Silver DA, Pellicer I, Fair WR. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85
9 Budaus L, Leyh-Bannurah SR, Salomon G. et al. Initial Experience of (68)Ga‐PSMA PET/CT Imaging in High‐risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016; 69: 393-396
10 Maurer T, Gschwend JE, Rauscher I. et al. Diagnostic Efficacy of (68)Gallium‐PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer. J Urol 2016; 195: 1436-1443
11 Rowe SP, Gorin MA, Allaf ME. et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 2016; 19: 223-230
12 Kesch C, Kratochwil C, Mier W. et al. Ga-68 or F-18 for Prostate Cancer Imaging?. J Nucl Med 2017; 58: 687-688
13 Rahbar K, Weckesser M, Ahmadzadehfar H. et al. Advantage of F-PSMA-1007 over Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion. Eur J Nucl Med Mol Imaging 2018;
14 Dietlein M, Kobe C, Kuhnert G. et al. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer. Mol Imaging Biol 2015; 17: 575-584
15 Giesel F, Will L, Lawal I. et al. Intra-individual comparison ofF-PSMA-1007 and F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: A pilot study. J Nucl Med 2017;
16 Steiger P, Thoeny HC. Prostate MRI based on PI-RADS version 2: how we review and report. Cancer Imaging 2016; 16: 9
17 Hamoen EHJ, De rooij M, Witjes JA. et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol 2015; 67: 1112-1121
18 Ruprecht O, Weisser P, Bodelle B. et al. MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol 2012; 81: 456-460
19 De rooij M, Hamoen EH, Fütterer JJ. et al. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol 2014; 202: 343-351
20 Eiber M, Weirich G, Holzapfel K. et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Uro 2016;
21 Koerber SA, Utzinger MT, Kratochwil C. et al. Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. J Nucl Med 2017; 58: 1943-1948
22 Kesch C, Vinsensia M, Radtke JP. et al. Intraindividual Comparison ofF-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. J Nucl Med 2017; 58: 1805-1810
23 Budäus L, Leyh-Bannurah SR, Salomon G. et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol 2016; 69: 393-396
24 Cornford P, Bellmunt J, Bolla M. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Eur Urol 2017; 71: 630-642
25 Heidenreich A, Pfister D, Merseburger A. et al. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know. Eur Urol 2013; 64: 260-265
26 Afshar-oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209
27 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674
28 Dietlein F, Kobe C, Neubauer S. et al. PSA-Stratified Performance of F- and Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med 2017; 58: 947-952
29 Afshar-Oromieh A, Holland-Letz T, Giesel FL. et al. Diagnostic performance ofGa-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-1268
30 Perera M, Papa N, Christidis D. et al. Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016; 70: 926-937
31 Rauscher I, Düwel C, Haller B. et al. Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;
32 Giesel FL, Will L, Kesch C. et al. Biochemical Recurrence of Prostate Cancer: Initial Results with [F]PSMA-1007 PET/CT. J Nucl Med 2018; 59: 632-635
33 Giesel FL, Knorr K, Spohn F. et al. [18F]PSMA-1007 PET/CT in 166 Patients with BCR after radical prostatectomy, SNMMI-A-2839-2018. 2018
34 Rahbar K, Ahmadzadehfar H, Kratochwil C. et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 2017; 58: 85-90
35 Kratochwil C, Bruchertseifer F, Giesel FL. et al. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. J Nucl Med 2016; 57: 1941-1944
36 Abdollah F, Sood A, Sammon JD. et al. Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients. Eur Urol 2015; 68: 497-505
37 Abdollah F, Gandaglia G, Suardi N. et al. More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 2015; 67: 212-219
38 Moschini M, Carroll PR, Eggener SE. et al. Low-risk Prostate Cancer: Identification, Management, and Outcomes. Eur Urol 2017;
39 Sooriakumaran P, Karnes J, Stief C. et al. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. Eur Urol 2015; 69: 788-794
40 Hovels AM, Heesakkers RA, Adang EM. et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-395
41 Schiavina R, Scattoni V, Castellucci P. et al. 11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. Eur Urol 2008; 54: 392-401
42 Heck MM, Souvatzoglou M, Retz M. et al. Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [(11)C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 2014; 41: 694-701
43 Heidenreich A, Ohlmann CH, Polyakov S. Anatomical Extent of Pelvic Lymphadenectomy in Patients Undergoing Radical Prostatectomy. Eur Urol 2007; 52: 29-37
44 Giesel FL, Fiedler H, Stefanova M. et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1794-1800
45 Brogsitter C, Zöphel K, Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: Comparative analysis for imaging prostate cancer patients. Eur J Nucl Med Mol Imaging 2013; 40: 18-27
46 Herlemann A, Wenter V, Kretschmer A. et al. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. Eur Urol 2016; 1-5
47 Vinsensia M, Chyoke P, Hadaschik B. et al. 68Ga-PSMA PET/CT and volumetric morphology of PET-positive lymph nodes stratified by tumor differentiation of prostate cancer. JNM 2017;
48 Zamboglou C, Wieser G, Hennies S. et al. MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 889-897
49 Zamboglou C, Drendel V, Jilg CA. et al. Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 2017; 7: 228-237
50 van Leeuwen PJ, Emmett L, Ho B. et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017; 119: 209-215
51 Uprimny C, Kroiss AS, Fritz J. et al. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Eur J Nucl Med Mol Imaging 2017; 44: 1647-1655
52 Freitag MT, Radtke JP, Afshar-Oromieh A. et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68 Ga-PSMA-11-PET of PET / CT and PET / MRI : comparison with mpMRI integrated in simultaneous PET / MRI. Eur J Nucl Med Mol Imaging 2016;
53 Giesel FL, Hadaschik B, Cardinale J. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging 2016;
54 Mohler JL, Kantoff PW, Armstrong AJ. et al. Prostate Cancer, Version 1. 2016 Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 2016; 14: 19-30
55 Rauscher I, Maurer T, Beer AJ. et al. Value of 68Ga-PSMA HBED-CC PET for the Assessment of Lymph Node Metastases in Prostate Cancer Patients with Biochemical Recurrence: Comparison with Histopathology After Salvage Lymphadenectomy. J Nucl Med 2016; 57: 1713-1719
56 Jilg CA, Rischke HC, Reske SN. et al. Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 2012; 188: 2190-2197
57 Suardi N, Gandaglia G, Gallina A. et al. Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. Eur Urol 2014; 67: 299-309
58 Abdollah F, Briganti A, Montorsi F. et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 2015; 67: 839-849
59 Jilg CA, Drendel V, Rischke HC. et al. Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-ligand-PET/CT Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer. Theranostics 2017; 7: 1770-1780
60 Maurer T, Weirich G, Schottelius M. et al. Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur Urol 2015; 68: 530-534
61 Rauscher I, Düwel C, Wirtz M. et al. Value of (111) In-PSMA-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up. BJU Int 2016;
62 Robu S, Schottelius M, Eiber M. et al. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med 2016; 00: 00-00 #((Band, Seiten?))
63 Rowe S, Pienta K, Pomper MG. et al. Proposal of a Structured Reporting System for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging: PSMA-RADS Version 1.0. J Nucl Med 2017;
64 Rowe SP, Pienta KJ, Pomper MG. et al. PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies. Eur Urol 2018; 73: 485-487
65 Fanti S, Minozzi S, Morigi JJ. et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging 2017; 1-14
66 Gupta SK, Watson T, Denham J. et al. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning. Int J Radiat Oncol Biol Phys 2017; 99: 701-709
67 Habl G, Sauter K, Schiller K. et al. (68) Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment. Prostate 2017; 77: 920-927
68 Schmidt-Hegemann NS, Fendler WP, Buchner A. et al. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiat Oncol 2017; 12: 176
69 Ost P, Reynders D, Decaestecker K. et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol 2018; 36: 446-453
70 Schiller K, Devecka M, Maurer T. et al. Impact of (68)Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology – a patterns of failure analysis in patients with primary diagnosis of prostate cancer. Radiat Oncol 2018; 13: 36
71 Dewes S, Schiller K, Sauter K. et al. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study. Radiat Oncol 2016; 11: 73
72 Roach PJ, Francis R, Emmett L. et al. The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. J Nucl Med 2018; 59: 82-88
73 Stish BJ, Pisansky TM, Harmsen WS. et al. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. J Clin Oncol 2016; 34: 3864-3871